Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa monotherapy for previously platinum-treated advanced urothelial cancer
NL-OMON50165Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in transitional cell carcinoma (TCC) and bladder cancer, sponsored by GSK. Primary endpoint: Confirmed overall response. Started Jul 2020; status: active, not recruiting.
02
Drugs
bintrafusp alfa
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON50165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50165.